Elevated circulating levels of CTRP9 in T2DM and coronary artery disease patients suggest a compensatory response aiming to restore a functional balance to insulin resistance, the inflammatory environment, and endothelial dysfunction in these patients (Moradi et al., 2018). This evidence concerns the gene C1QTNF9 and type 2 diabetes mellitus.